NCT01538667 - Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Respiratory System

Interventions

DRUG

Ciprofloxacin (Cipro Inhale, BAYQ3939)

50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects

DRUG

Ciprofloxacin (Cipro Inhale, BAYQ3939)

50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block

DRUG

Ciprofloxacin (Cipro Inhale, BAYQ3939)

50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients

DRUG

Ciprofloxacin (Cipro Inhale, BAYQ3939)

50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients

Trial Locations (1)

Gauting